The New York Genome Center has a nice round up post on Clinical Genomics talks from day two of the Advances in Genome Biology and Technology conference. You can see all their posts from the meeting on their website.

The FDA has approved TDM-1 for breast cancer, according to coverage from Reuters. Here is a brief item from Forbes about the drug and its cost, A Triumph in Breast Cancer–And Another Expensive Drug. (A number of people on Twitter have commented that the brand name is Kadcyla a bit close to Kalydeco, a drug used in the treatment of cystic fibrosis.)

On Thursday, the NIH announced a new US policy for research with potentially risky subjects requiring stricter controls, such as H5N1.  The LA Times has coverage, and this post from the Nature News Blog includes a number of helpful links, as well as official opportunities for public comment on the policy related to this type of research, referred to as “dual-use research of concern”.

The Washington Post WonkBlog explains a new regulation on how insurance companies must cover colonoscopies under the Affordable Care Act.